Abstract

BackgroundMethotrexate (MTX) is the DMARD of first choice in patients with juvenile idiopathic arthritis (JIA). However, limited data is available on MTX survival, including reasons for stopping MTX, and predictors...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study.
Fatema Merali ...
The Lancet. Rheumatology | VOL. 3
Fatema Merali, et. al.Fatema Merali ...
04 Dec 2020
AB0901 Trends in Paediatric Rheumatology Referral Times and Disease Activity Indices over A Ten-Year Period among Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Prospective Study (CAPS)
W Thomson ... A.S.E Chieng
Annals of the Rheumatic Diseases | VOL. 73
W Thomson, et. al.W Thomson ... A.S.E Chieng
01 Jun 2014
THU0307 Validation of JADAS in international league against rheumatism (ILAR) subtypes of juvenile idiopathic arthritis (JIA)
W Thomson ... J Davidson
Annals of the Rheumatic Diseases | VOL. 71
W Thomson, et. al.W Thomson ... J Davidson
01 Jun 2013
P02 Multi-trajectories of disease activity in juvenile idiopathic arthritis
Kimme Hyrich ... Wendy Thomson
Rheumatology | VOL. 58
Kimme Hyrich, et. al.Kimme Hyrich ... Wendy Thomson
30 Sep 2019
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers